In 2013, the FDA approved the first successful HER2-targeted antibody–drug conjugate, trastuzumab emtansine (T-DM1; Kadcyla; Genentech), for the treatment of HER2-positive trastuzumab-pretreated advanced breast cancer. Here, ERBB2 is linked to breast cancer.